Although FOXO1 must be excluded from the nucleus becoming inactive in myoblasts during myogenesis [22], we found FOXO1 expressed in the nuclei of all ALS patient myoblasts as well as in TDP-43- or FUS-silenced myoblasts, suggesting this change as a consistent pathogenic feature in ALS muscle. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.